The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Novo is paying up to $1 billion for a “non-incretin” medicine that might boost Wegovy’s effects. Elsewhere, Arbutus laid off ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Bank of America (NYSE:BAC) (BofA) on Friday lowered its price target for Novo Nordisk (CSE:NOVOb)k (NYSE:NVO) shares, cautioning that the company may miss its first-quarter earnings projections as ...

Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...

China's state-owned Eastern Airlines said on Friday its net loss shrank to 4.2 billion yuan ($578 million) in 2024 from a 8.2 ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

The proposed UK assisted dying law may be delayed until 2029, raising doubts about its future. Novo Nordisk's shares tumble ...

Stock futures were lower on Wednesday, as investors weighed news on President Donald Trump's 25% tariff aimed at foreign cars ...

“ The growing use of GLP-1 medications like Ozempic and Wegovy is reshaping consumer demand in grocery stores, particularly ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

The two stocks have been trending in different directions for months. Here's what that says about the broader market.